Trending...
- The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph
- Eastern Adjustment Group, LLP Provides Property Loss Advocacy and Claim Support
- Bishop Mary's WWDB 860 AM Show Nears Historic 250-Episode Milestone
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 6, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) securities between April 30, 2021 and August 31, 2021, inclusive (the "Class Period").
Investors suffering losses on their AbbVie investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
AbbVie's Janus kinase ("JAK") inhibitor drug, Rinvoq, has been approved by the U.S. Food and Drug Administration ("FDA") for the treatment of moderate to severe rheumatoid arthritis ("RA"). In 2020, AbbVie sought regulatory approval to expand the indications for Rinvoq.
On June 25, 2021, AbbVie disclosed that the FDA would not complete its review of several of the expanded treatment indications for Rinvoq within the previously-announced timeframe due to its ongoing evaluation of safety concerns associated with other JAK inhibitor drugs.
More on The PennZone
On this news, AbbVie's common stock fell $1.76, or 1.5%, to close at $112.98 per share on June 25, 2021, thereby injuring investors.
Then, on September 1, 2021, the FDA announced that the safety trials for another JAK inhibitor drug, Xeljanz, had established an increased risk of serious adverse events, even with low doses, and determined that new and updated warnings would be required for those drugs as well as for Rinvoq, as it shares "similar mechanisms of action" and "may have similar risks." The FDA also disclosed that it would further limit approved indications for Rinvoq as a result of safety concerns.
On this news, AbbVie's common stock fell $8.51, or 7%, to close at $112.27 per share on September 1, 2021, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
If you purchased or otherwise acquired AbbVie securities during the Class Period, you may move the Court no later than June 6, 2022 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Investors suffering losses on their AbbVie investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
AbbVie's Janus kinase ("JAK") inhibitor drug, Rinvoq, has been approved by the U.S. Food and Drug Administration ("FDA") for the treatment of moderate to severe rheumatoid arthritis ("RA"). In 2020, AbbVie sought regulatory approval to expand the indications for Rinvoq.
On June 25, 2021, AbbVie disclosed that the FDA would not complete its review of several of the expanded treatment indications for Rinvoq within the previously-announced timeframe due to its ongoing evaluation of safety concerns associated with other JAK inhibitor drugs.
More on The PennZone
- Evermore Bliss Launches AI Wedding Speech Writer to Help Users Create Personalized, Heartfelt Toasts
- Keenethics enters the ChatGPT Apps ecosystem as a new growth opportunity for businesses
- Spring Into Your New Home at Heritage at South Brunswick
- ULiveUSA Launches New "Moment Marketing" System Using Videos to Help Local Businesses Get More Customers
- UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
On this news, AbbVie's common stock fell $1.76, or 1.5%, to close at $112.98 per share on June 25, 2021, thereby injuring investors.
Then, on September 1, 2021, the FDA announced that the safety trials for another JAK inhibitor drug, Xeljanz, had established an increased risk of serious adverse events, even with low doses, and determined that new and updated warnings would be required for those drugs as well as for Rinvoq, as it shares "similar mechanisms of action" and "may have similar risks." The FDA also disclosed that it would further limit approved indications for Rinvoq as a result of safety concerns.
On this news, AbbVie's common stock fell $8.51, or 7%, to close at $112.27 per share on September 1, 2021, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
- HarryPotterObamaSonic10Inu (Ticker: BITCOIN) Is the Best Cryptocurrency in Global History
- Colonial Nissan Highlights 2026 Armada after Major Best Buy Award Win
- Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
- The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph
- Additions of Tennant, Morrissey, Cummings, Hale Highlight Fandoms at FAN EXPO Philadelphia
If you purchased or otherwise acquired AbbVie securities during the Class Period, you may move the Court no later than June 6, 2022 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Filed Under: Business
0 Comments
Latest on The PennZone
- AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
- BestDoc Launches AI Call Center for Healthcare
- Authentise Launches "Whisper," Agentic AI Backbone for Engineering & Manufacturing
- Old Economy Village Invites Visitors to Explore its 2026 Event Season
- Acuvance Appoints Sandeep Sabharwal to Board of Directors, Strengthening Leadership to Support Continued Platform Growth
- Grange Insurance Association to Rebrand as Granwest Insurance on July 1, 2026
- Dr. Rosendo Icochea, MD Recognized for Contributions to Surgical Education and Medical Research
- Giftella Launches AI Gift-Finder App That Replaces Guesswork With Personalized Picks in Seconds
- Beverly.io Announces Nationwide Expansion and Poppins Payroll Partnership for Families
- Collectors gathered 'round the playing circle to compete for the rarest and best examples at Morphy's April 11 Premier Marbles auction
- New Book: The Battle for Truth and Shadows - Guardians of Light - Epic Fantasy Unveils a War Between Light and Deception
- Clash of Prompts: The World's First AI Prompt Battle Royale
- $7.6 Billion US Crypto ATM Market by 2034; California and Texas Crypto ATM Deployments for Bitcoin Bancorp (Stock Symbol: BCBC); 1000 Kiosk Inventory
- MainConcept Announces Multiview Encoding for Apple Immersive Video
- CCHR Rejects Global Psychiatric Push to Electroshock Children
- iVAM2-ST2110 to Simplify IP Transitions and Reduce Monitoring Complexity
- Americans Leave Behind or Discard 42% of Their Belongings When Moving Out for the First Time, Talker Research Finds
- Central Florida Luxury Real Estate Firm DANHOLM COLLECTION Partners with Luxury Presence to Expand Global Buyer Reach
- Advantage Marketing Launches 3-Minute Assessment to Help SMBs Diagnose and Fix Marketing Gaps
- RemodelCalculators.com Launches 15 Free Home Renovation Tools